Stifel 2026 Healthcare Conference 2026
Logotype for Oculis Holding AG

Oculis (OCS) Stifel 2026 Healthcare Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Oculis Holding AG

Stifel 2026 Healthcare Conference 2026 summary

11 Nov, 2026

Privosegtor clinical results and development

  • Phase II ACUITY showed 18-letter LCVA improvement at month 3, retinal ganglion cell preservation, reduced neurofilament and GFAP, and good safety; received FDA Breakthrough Therapy and EMA PRIME designations, and is now in Phase III.

  • PIONEER-1 is an event-driven optic neuritis trial; the first patient was dosed in late August, U.S. screening and randomization are underway, and enrollment is starting in Europe.

  • Plan is to activate 60 sites, with half targeted by year-end 2026; randomization is expected to finish in 2027, with topline potentially around year-end 2027, subject to refinement after 50% enrollment.

  • PIONEER-1 primary endpoint is LCVA; key secondary endpoints include GCIPL and neurofilament, with GFAP exploratory. Treatment is 5 days, readout at month 3, and 100 patients will be followed to month 12 for the FDA safety database.

  • Development strategy prioritizes inflammatory indications—optic neuritis and acute MS relapse—before ischemic NAION; NAION remains a hypothesis requiring human validation in a planned Phase II/III study.

Licaminlimab and dry-eye strategy

  • Licaminlimab targets TNFR1-positive dry-eye patients; RELIEF showed 5x greater signs improvement and 7x greater symptoms improvement in this subgroup, and FDA agreed to TNFR1-enriched Phase III testing.

  • PREDICT-1 is a symptom trial with mean improvement in TNFR1-positive patients as the primary endpoint, all-comers as a secondary endpoint, and responder improvement of more than 20 points also assessed; two-thirds of patients are expected to be TNFR1-positive.

  • Base-case program is two signs and two symptoms trials, planned for 650 patients; after PREDICT-1, the team plans to meet FDA, which could require only one additional signs trial.

  • TNFR1 testing uses a rapid, noninvasive saliva-swab qPCR; the intended strategy is test-and-treat for an estimated 1.5 million moderate-to-severe TNFR1-positive patients.

  • PREDICT-1 results are expected in December 2026 or January 2027.

Pipeline plans and financial position

  • At the December 8, 2026 R&D Day, management plans to update PIONEER-1 execution and provide protocol detail for PIONEER-2 and PIONEER-3; an IND for PIONEER-3 was expected in Q4 2026.

  • PIONEER-1 includes optic neuritis broadly, excluding AQP4/NMO from the mITT; management expects roughly two-thirds MS and one-third non-MS patients. PIONEER-2 focuses on optic neuritis in MS patients.

  • Privosegtor is administered by IV infusion; an oral formulation is the most advanced alternative being developed, while drop and intravitreal formulations remain early-stage.

  • Cash was CHF 252 million, expected to fund operations through H2 2029, including PIONEER-1, PIONEER-2, PIONEER-3 and PREDICT-1; this excludes the BlackRock loan facility.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Oculis